Publication Name	World Journal of Diabetes
Manuscript ID	80829
Country	South Africa

Received	2022-10-13 21:31
Peer-Review Started	2022-10-13 21:34
To Make the First Decision
Return for Revision	2022-11-27 05:31
Revised	2022-12-31 13:21
Second Decision	2023-06-08 03:19
Accepted by Journal Editor-in-Chief	2023-06-10 00:46
Accepted by Executive Editor-in-Chief	2023-06-13 08:52
Articles in Press	2023-06-13 08:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-07-05 12:23
Publish the Manuscript Online	2023-07-13 08:03

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medical Ethics
Manuscript Type	Opinion Review
Article Title	Access to novel anti-diabetic agents in resource limited settings: A brief commentary
Manuscript Source	Invited Manuscript
All Author List	Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand and Rory F Leisegang
ORCID	Author(s) ORCID Number Poobalan Naidoo http://orcid.org/0000-0002-5950-1585 Kiolan Naidoo http://orcid.org/0000-0002-5435-8345 Sumanth Karamchand http://orcid.org/0000-0003-4435-6685 Rory F Leisegang http://orcid.org/0000-0003-0810-4771
Funding Agency and Grant Number
Corresponding Author	Poobalan Naidoo, BPharm, MBChB, MSc, Academic Research, Doctor, Doctor, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Sydney Road, Umbilo, Durban 4001, Kwa-Zulu Natal , South Africa. poobalan1naidoo@yahoo.com
Key Words	Type 2 diabetes mellitus; Novel anti-diabetic agents; Resource limited settings; Access
Core Tip	The manuscript addresses the problem of access to novel anti-diabetic agents in resource limited settings. Niching therapies for use in those with highest major adverse cardiovascular risk, may limit budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.
Publish Date	2023-07-13 08:03
Citation	Naidoo P, Naidoo K, Karamchand S, Leisegang RF. Access to novel anti-diabetic agents in resource limited settings: A brief commentary. World J Diabetes 2023; 14(7): 939-941
URL	https://www.wjgnet.com/1948-9358/full/v14/i7/939.htm
DOI	https://dx.doi.org/10.4239/wjd.v14.i7.939

Full Article (PDF)	WJD-14-939-with-cover.pdf
Full Article (Word)	WJD-14-939.docx
Manuscript File	80829_Auto_Edited-JLW.docx
Answering Reviewers	80829-Answering reviewers.pdf
Audio Core Tip	80829-Audio core tip.wav
Conflict-of-Interest Disclosure Form	80829-Conflict-of-interest statement.PDF
Copyright License Agreement	80829-Copyright license agreement.pdf
Peer-review Report	80829-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	80829-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	80829-CrossCheck.png
Scientific Misconduct Check	80829-Bing-Gong ZM-2.jpg
Scientific Editor Work List	80829-Scientific editor work list.pdf
CrossCheck Report	80829-CrossCheck report.pdf